CSL Ltd (ASX: CSL) shares have clawed back serious ground in recent months, climbing 10% over the past month and 29% over the past six months. Even so, the ASX biotech stock remains 12% below where it stood a year ago.
The next test looms larger, though: the psychological $200 barrier. Clearing it won't be a gimme. The $85 billion healthcare giant still has to prove it can deliver on several fronts before that milestone becomes more than just a broker's spreadsheet fantasy.
The good news? CSL has actually laid out the roadmap. Now it just has to walk it.
Image source: Getty Images
The Behring problem, and the Behring fix
Everything starts with CSL Behring, by far the group's biggest business and the one that's caused the most headaches. After a rough patch, management is now promising a return to mid-single-digit revenue growth in FY27, with immunoglobulin sales expected to climb at a mid-to-high single-digit clip.
That's not just corporate optimism. Demand for immunoglobulin remains genuinely strong, and CSL is squeezing more out of its plasma collection and manufacturing process at the same time. If Behring turns the corner, it drags the whole group with it.
New kids on the block
CSL isn't relying on Behring alone. ANDEMBRY and HEMGENIX both posted strong uptake in FY26, and management expects that momentum to keep building.
If these newer therapies can scale into genuine earnings contributors, they give CSL something it's lacked for a while: a growth story that doesn't depend entirely on plasma.
Cost-cutting isn't just noise
CSL's transformation program has actual receipts. The company banked around US$176 million in cost savings during FY26 – ahead of schedule – with more coming in FY27. Roughly half of those incremental savings are being ploughed straight back into growth initiatives.
If revenue growth and cost discipline both fire at once, that's a genuine earnings tailwind, not just a management slide deck promise.
The part nobody wants to talk about
Here's the catch. CSL expects Vifor revenue to fall roughly 25% in FY27, hammered by generic competition in iron products. Seqirus, meanwhile, is only expected to scrape out low-single-digit growth.
Translation: Behring and the new therapies need to do the heavy lifting almost entirely on their own, while the rest of the portfolio does its best impression of dead weight.
Brokers are starting to bite
That improving – if uneven – outlook is enough to get some brokers genuinely excited. In September, RBC Capital Markets upgraded CSL to outperform and hiked its price target from $148 all the way to $213. That points to a 21% upside at the current share price level.
RBC's bullish call rests on a simple bet: that Behring's recovery can outrun the drag from Vifor and Seqirus, and earnings growth returns from here.
Barrenjoey followed with an upgrade to overweight and a $180 target.
Not everyone's convinced. Citi is stuck at hold with a $160 target, while UBS sits at buy with $181.
Foolish takeaway
The path to $200 isn't a straight line. It's a bet that demand for immunoglobulins stays strong, new therapies scale quickly, cost savings keep flowing, and the weak links stop bleeding.
Leadership uncertainty adds another variable to the $200 case. In a notice of annual general meeting lodged with the ASX last week, CSL chair Brian McNamee said the search for a new Chief Executive Officer was well-advanced, though still ongoing.
Investors will want clarity on who's steering the recovery before fully buying into it.
That's a lot of boxes to tick. But if CSL ticks them, $200 starts looking like the obvious next stop.
